Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2016 1
2021 1
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell.
Khan S, Ahmad SS, Kamal MA. Khan S, et al. Endocr Metab Immune Disord Drug Targets. 2021;21(2):268-281. doi: 10.2174/1871530320666200731174724. Endocr Metab Immune Disord Drug Targets. 2021. PMID: 32735531 Review.
Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus characterized by gradually failing heart with detrimental cardiac remodelings, such as fibrosis and diastolic and systolic dysfunction, which is not directly attributable to coronary ar …
Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus characterized by gradually failing heart with detrimental …
Is it time for the practical application of biomarkers in chronic heart failure management?
Słonina G, Zemleduch T, Kimla P, Kudliński B. Słonina G, et al. Pol Merkur Lekarski. 2022 Apr 19;50(296):73-77. Pol Merkur Lekarski. 2022. PMID: 35436267
RESULTS: Currently, only natriuretic peptides, reflecting pressure overload of the heart, and cardiac troponins, are recognized and used in practice diagnostic biomarkers of heart failure. Numerous plasma substances are being studied such as: galectin-3, ST-2 protein, MR-p …
RESULTS: Currently, only natriuretic peptides, reflecting pressure overload of the heart, and cardiac troponins, are recognized and u …
Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex-specific differences of glucose-lowering therapies on the diabetic heart: IUPHAR Review 33.
Sharma A, De Blasio M, Ritchie R. Sharma A, et al. Br J Pharmacol. 2023 Nov;180(22):2916-2933. doi: 10.1111/bph.15820. Epub 2022 Mar 10. Br J Pharmacol. 2023. PMID: 35174479 Free PMC article. Review.
Several structural features underlie the development of diabetic cardiomyopathy and eventual diabetes-induced heart failure. Pathological cardiac fibrosis (interstitial and perivascular), in addition to capillary rarefaction and myocardial apoptosis, are part …
Several structural features underlie the development of diabetic cardiomyopathy and eventual diabetes-induced heart failure. Pathological …
Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment.
Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, Barry V, Mikels-Vigdal A, Karpinski S, Kornyeyev D, Adamkewicz J, Feng X, Zhou Q, Shang C, Kumar P, Phan D, Kasner M, López B, Diez J, Wright KC, Kovacs RL, Chen PS, Quertermous T, Smith V, Yao L, Tschöpe C, Chang CP. Yang J, et al. Nat Commun. 2016 Dec 14;7:13710. doi: 10.1038/ncomms13710. Nat Commun. 2016. PMID: 27966531 Free PMC article.
Interstitial fibrosis plays a key role in the development and progression of heart failure. ...In mice, cardiac stress activates fibroblasts to express and secrete Loxl2 into the interstitium, triggering fibrosis, systolic and diastolic dysfunction of …
Interstitial fibrosis plays a key role in the development and progression of heart failure. ...In mice, cardiac stress …
Identification of a Hydrogen-Sulfide-Releasing Isochroman-4-One Hybrid as a Cardioprotective Candidate for the Treatment of Cardiac Hypertrophy.
Wang Y, Liu Y, Wu H, Xu S, Ma F. Wang Y, et al. Molecules. 2022 Jun 27;27(13):4114. doi: 10.3390/molecules27134114. Molecules. 2022. PMID: 35807360 Free PMC article.
Cardiac pathological hypertrophy is associated with undesirable epigenetic changes and causes maladaptive cardiac remodeling and heart failure, leading to high mortality rates. ...The 13-E protected against cardiomyocyte hypertrophy In Vitro and reduced the inductio …
Cardiac pathological hypertrophy is associated with undesirable epigenetic changes and causes maladaptive cardiac remodeling a …
Hypertensive heart disease: effects of lifestyle modifications and antihypertensive drug treatment.
Grandi AM. Grandi AM. Expert Rev Cardiovasc Ther. 2004 Jul;2(4):617-25. doi: 10.1586/14779072.2.4.617. Expert Rev Cardiovasc Ther. 2004. PMID: 15225120 Review.
This review will focus on hypertensive heart disease that is mainly characterized by myocardial hypertrophy and increased interstitial fibrosis. Cardiac remodeling develops as an adaptive response but actually represents a powerful independent risk factor for …
This review will focus on hypertensive heart disease that is mainly characterized by myocardial hypertrophy and increased interstitial …